Nelociguat BAY60-4552,99.73%
产品编号:Bellancom-78237| CAS NO:625115-52-8| 分子式:C19H17FN8O2| 分子量:408.39
Nelociguat (BAY60-4552)是一种一氧化氮敏感的可溶性的鸟苷酸环化酶激活物。
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
Nelociguat BAY60-4552
产品介绍 | Nelociguat (BAY60-4552)是一种一氧化氮敏感的可溶性的鸟苷酸环化酶激活物。 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | Nelociguat (BAY60-4552) is a nitric oxide sensitive soluble guanylate cyclase stimulator. | ||||||||||||
体外研究 |
Soluble guanylate cyclase (sGC) is a key enzyme in the nitric oxide (NO) signalling pathway. Riociguat is metabolized to BAY60-4552 not only via cytochrome P450 isoenzymes 3A4 (CYP3A4), CYP2C8, and CYP2J2, but also via CYP1A1, located in the liver and lungs. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||
体内研究 |
GSK2181236A and BAY 60-4552 provide partial benefit against hypertension-induced end-organ damage. In spontaneously hypertensive stroke-prone rats, a low dose of BAY 60-4552 decreases urine output and improved survival. A high dose also reduces urine output, and in addition reduces microalbuminuria and attenuates the increase in mean arterial pressure. Both the 0.3 and 3 mg/kg/day doses of BAY 60-4552 improves survival of 46 and 69%. Seven weeks of treatment with BAY 60-4552 (0.3 and 3.0 mg/kg/day) dose-dependently decreases urine output to 79±11 and 56±10 mL/day. BAY 60-4552, and vardenafil provides synergistic beneficial effects and might therefore salvage patients who experience treatment failures with PDE5 inhibitors after radical prostatectomy. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||
体内研究 |
GSK2181236A and BAY 60-4552 provide partial benefit against hypertension-induced end-organ damage. In spontaneously hypertensive stroke-prone rats, a low dose of BAY 60-4552 decreases urine output and improved survival. A high dose also reduces urine output, and in addition reduces microalbuminuria and attenuates the increase in mean arterial pressure. Both the 0.3 and 3 mg/kg/day doses of BAY 60-4552 improves survival of 46 and 69%. Seven weeks of treatment with BAY 60-4552 (0.3 and 3.0 mg/kg/day) dose-dependently decreases urine output to 79±11 and 56±10 mL/day. BAY 60-4552, and vardenafil provides synergistic beneficial effects and might therefore salvage patients who experience treatment failures with PDE5 inhibitors after radical prostatectomy. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||
性状 | Solid | ||||||||||||
溶解性数据 |
In Vitro:
DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble) In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||
储存方式 |
| ||||||||||||
参考文献 |
|
海关编码 | 2933990090 |
---|

匹配竞争对手的价格

效率为先

专业经验 贴心服务

50000+库存